

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 December 2000 (14.12.2000)

PCT

(10) International Publication Number
WO 00/75664 A1

(51) International Patent Classification⁷: G01N 33/543, 33/53

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/US00/15774

(22) International Filing Date: 9 June 2000 (09.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/138,311 9 June 1999 (09.06.1999) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): L JL BIOSYSTEMS, INC. [US/US]; 404 Tasman Drive, Sunnyvale, CA 94089 (US).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

(72) Inventors; and

(75) Inventors/Applicants (for US only): SPORTSMAN, J., Richard [US/US]; 4154 Amaranta Court, Palo Alto, CA 94306 (US). KAUVAR, Lawrence, M. [US/US]; 1489 Webster Street #521, San Francisco, CA 94115 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(74) Agents: ABNEY, James, R. et al.; Kolisch, Hartwell, Dickinson, McCormack & Heuser, Suite 200, 520 S.W. Yamhill Street, Portland, OR 97204 (US).



WO 00/75664 A1

(54) Title: IMPROVEMENTS IN LUMINESCENCE POLARIZATION ASSAYS

(57) Abstract: The improvements may include using confocal optics to increase sensitivity and accuracy, providing additional classes of tracers, providing improved methods to prepare specific luminescent tracers, and/or expanding the scope of assay targets, among others.

IMPROVEMENTS IN LUMINESCENCE POLARIZATION ASSAYS

Cross-References to Related Applications

This application is based upon and claims priority under 35 U.S.C. 5 § 119 from the following U.S. Provisional Patent Application, which is incorporated herein by reference: Serial No. 60/138,311, filed June 9, 1999.

This application incorporates by reference the following U.S. patent applications: Serial No. 08/840,553, filed April 14, 1997; Serial No. 08/929,095, filed September 15, 1997; Serial No. 09/118,141, filed July 16, 10 1998; Serial No. 09/144,575, filed August 31, 1998; Serial No. 09/144,578, filed August 31, 1998; Serial No. 09/146,081, filed September 2, 1998; Serial No. 09/156,318, filed September 18, 1998; Serial No. 09/160,533, filed September 24, 1998; Serial No. 09/302,158, filed April 29, 1999; Serial No. 09/349,733, filed July 8, 1999; Serial No. 09/468,440, filed December 21, 15 1999; Serial No. 09/478,819, filed January 5, 2000; Serial No. 09/494,407, filed January 28, 2000; and Serial No. 09/556,030, filed April 20, 2000.

This application also incorporates by reference the following PCT patent applications: Serial No. PCT/US99/01656, filed January 25, 1999; Serial No. PCT/US99/03678, filed February 19, 1999; Serial No. PCT/US99/08410, 20 filed April 16, 1999; Serial No. PCT/US99/16057, filed July 15, 1999; Serial No. PCT/US99/16453, filed July 21, 1999; Serial No. PCT/US99/16621, filed July 23, 1999; Serial No. PCT/US99/16286, filed July 26, 1999; Serial No. PCT/US99/16287, filed July 26, 1999; Serial No. PCT/US99/24707, filed October 19, 1999; Serial No. PCT/US00/00895, filed January 14, 2000; Serial 25 No. PCT/US00/03589, filed February 11, 2000; Serial No. PCT/US00/04543, filed February 22, 2000; Serial No. PCT/US00/06841, filed March 15, 2000; Serial No. PCT/US00/12277, filed May 3, 2000; Serial No. _____, filed June 9, 2000, entitled *Phosphorylation Assays*, of inventors Wei Huang, Merl F. Hoekstra, Sandra K. Lee, Nicholas Cairns, Lawrence M. Kauvar, and J.

Richard Sportsman; and Serial No. _____, filed June 9, 2000, entitled *Cell-Signaling Assays*, of inventors J. Richard Sportsman and Lawrence M. Kauvar.

This application also incorporates by reference the following U.S. provisional patent applications: Serial No. 60/138,438, filed June 10, 1999; 5 Serial No. 60/138,737, filed June 11, 1999; Serial No. 60/138,893, filed June 11, 1999; Serial No. 60/142,721, filed July 7, 1999; Serial No. 60/143,185, filed July 9, 1999; Serial No. 60/153,251, filed September 10, 1999; Serial No. 60/164,633, filed November 10, 1999; 60/165,813, filed November 16, 1999; Serial No. 60/167,301, filed November 24, 1999; Serial No. 60/167,463, filed 10 November 24, 1999; Serial No. 60/178,026, filed January 26, 2000; Serial No. 60/182,036, filed February 11, 2000; Serial No. 60/182,419, filed February 14, 2000; Serial No. 60/184,719, filed February 24, 2000; Serial No. 60/184,924, filed February 25, 2000; Serial No. 60/190,265, filed March 17, 2000; Serial 15 No. 60/191,890, filed March 23, 2000; Serial No. 60/193,586, filed March 30, 2000; Serial No. 60/197,324, filed April 14, 2000; Serial No. 60/200,530, filed April 27, 2000; Serial No. 60/200,594, filed April 28, 2000; and Serial No. _____, filed May 4, 2000, entitled *Nucleic Acid Detection Methods*, of inventors Susan S. Kalman and Enal S. Ravi.

This application also incorporates by reference the following 20 publications: K.E. van Holde, Physical Biochemistry (2nd ed. 1985); William Bains, Biotechnology from A to Z (1993); Richard P. Haugland, Handbook of Fluorescent Probes and Research Chemicals (6th ed. 1996); Joseph R. Lakowicz, Principles of Fluorescence Spectroscopy (2nd ed. 1999); Bob Sinclair, Everything's Great When It Sits on a Chip: A Bright Future for DNA 25 Arrays, 13 THE SCIENTIST, May 24, 1999, at 18; and Charles R. Cantor and Paul R. Schimmel, Biophysical Chemistry (1980).

Field of the Invention

The invention relates to luminescence assays. More particularly, the invention relates to improvements in luminescence polarization assays by using

confocal optics to increase sensitivity and accuracy, by providing additional classes of tracers, by providing improved methods to prepare specific luminescent tracers, and/or by expanding the scope of assay targets.

Background of the Invention

5 Luminescence is the absorption and subsequent re-emission of light by a luminescent molecule, or "luminophore." In a luminescence assay, a luminophore is included in a system, and properties of the light emitted by the luminophore are used to infer properties of the system. Such light may include fluorescence and phosphorescence, and such properties may include
10 concentration, binding, and enzymatic activity, among others.

Measurement of luminescence polarization to determine concentrations or binding is based on the principle that excitation of an anisotropic luminophore with polarized light results in emission of polarized light. The polarization will be reduced or lost if the physical orientation of the
15 luminophore changes during the lifetime of the luminophore. However, the polarization will be at least partially retained if the lifetime of the luminophore is shorter than the rotational correlation time (or "tumble time) of the molecule or complex (e.g., luminophore + binding partner) from which the luminescence is emitted. The larger the emitting moiety, the longer the tumble
20 time, because the tumble time is proportional to the volume of the luminophore. Thus, when a small luminescent tracer binds to a larger component, the tumble time is increased, and the degree of polarization observed is enhanced. This permits a homogeneous assay whereby the binding of a labeled tracer to a moiety that enhances its size (and thus tumble time) is
25 detected by an increase in the polarization of the luminescence emitted by the tracer. Polarization assays are described in more detail in Appendix 1.

There are a variety of formats in which this assay can be utilized. In one format, the concentration of an analyte in solution can be measured by supplying a labeled tracer that competes with the analyte for a binding moiety,

especially a binding moiety larger than the labeled tracer. In this "competitive" format, the concentration of the analyte is inversely correlated with the enhancement of luminescence polarization in the light emitted by the tracer when it competitively binds the common moiety. In another format, the 5 concentration of a target can be measured by supplying a labeled tracer that is capable of binding the target. In this case, the enhancement of polarization is a direct measure of the concentration of target. The target may further be, for example, an activated receptor, where activation can be indirectly measured by the directly measured concentration of a generated molecule or by its binding 10 to labeled tracer *per se*.

Many of the labeled tracers employed in luminescence polarization assays are luminescently labeled peptides that are ligands for specific receptors or competitors to antigens for binding to antibodies. For example, U.S. Patent No. 5,760,188 describes labeled peptide tracers for binding to the neuropeptide Y receptor. U.S. Patent No. 5,824,772 describes labeled peptides that bind the human somatostatin receptor. Its counterpart application, PCT Patent Application Serial No. PCT/CA96/00207, which is incorporated herein by reference, describes, generically, receptor binding assays using peptide-labeled, luminescent tracers in a homogeneous luminescence polarization based assay. 15 Additional such labeled peptides designed to bind to receptors are described in PCT Patent Application Serial No. PCT/CA97/00481, which is incorporated herein by reference.

Luminescence polarization assays are important tools in life sciences research and in high-throughput screening laboratories. However, current 25 assays suffer from a number of shortcomings. In particular, current assays involve only a limited number of tracers directed only to a limited number of targets. Thus, the use of such assays is relatively limited, especially for screening applications.

Summary of the Invention

The invention provides improvements to luminescence polarization assays by using confocal optics to increase sensitivity and accuracy, by providing additional classes of tracers, by providing improved methods to 5 prepare specific luminescent tracers, and/or by expanding the scope of assay targets.

Brief Description of the Drawings

Figure 1 shows a comparison of the results for a tyrosine kinase assay using the confocal optics/microplate of the invention as compared to 10 conventional luminescence polarization.

Figure 2 shows a titration plot according to the equilibrium method of the invention for determination of K_d characterizing the binding of labeled theophylline to a monoclonal antibody Mab-8.

Figure 3 shows a determination of the on/off rate constants for labeled 15 theophylline with regard to Mab-10, a different monoclonal antibody.

Detailed Description

The invention is directed to a multiplicity of improvements in homogeneous luminescence polarization assay techniques. The improvements may include using confocal optics to increase sensitivity and accuracy, 20 providing additional classes of tracers, providing improved methods to prepare specific luminescent tracers, and/or expanding the scope of assay targets, among others.

In one aspect, the invention is directed to an improved method for conducting a luminescence polarization microplate assay, where the 25 improvement comprises using confocal optics to measure the luminescence polarization of the emitted light. The sensitivity and precision of the system is thereby enhanced to a level of 3 mP (millipolarization units) standard deviation at 1 nM fluorescein, whereas in commercially available instrumentation, the standard deviation was at this level at 10 nM fluorescein.

Most of the luminescent substrates intended for luminescence polarization or other luminescence assays comprise ligands containing a luminophore. Luminophores may have a variety of emission times and can generally be classified according to whether they have a short (0.1-10 nsec) or 5 long (10 nsec-1+ sec) emission time. Here, FL-S designates a short lifetime luminophore, and FL-L a long lifetime luminophore. Typical short-lifetime luminophores include, for example, the indopyra dyes, the coumarin dyes, fluorescein, FITC, Texas red, CY-5, phycoerythrin, dansyl, rhodamine, Lucifer yellow and the like. Typical long-lifetime luminophores include metal chelates, 10 such as the compositions described in PCT Patent Application Serial No. PCT/US00/03589, which is incorporated herein by reference.

In general, homogeneous luminescence polarization assays involve binding of a labeled tracer to an opposite member of a specific binding pair. By "opposite member of a specific binding pair" is meant one of two components 15 that bind to each other specifically to the exclusion of most other moieties on either side. Typical of such specific binding pairs, and most commonly thought of, are antigen/antibody interactions. However, other such interacting pairs would include, for example, receptors and their relevant ligands, biotin/avidin type interactions, complementary nucleotide sequences, triple helix forming 20 oligonucleotides and their target duplexes, and the like. In all cases, fragments of a specific binding pair member that retain their specificity and binding affinity for the opposite member can be substituted for the complete molecule. Any member of the pair also can be coupled to solid supports or other moieties 25 that may be useful in the context of the assays, including, of course, luminescent labels.

In another aspect, the invention is directed to a method to identify a successful tracer. In one embodiment, this is done by synthesizing candidate tracers in separate wells of a microplate and then exposing each well to a target labeled with a long-lifetime luminescent probe. Binding of the labeled target in

an individual well increases the tumble time beyond the emission lifetime even of the long-lifetime luminophore, and identifies that well as containing successful tracer. The tracer thus identified can then be labeled with a suitable luminophore, either before or after cleavage from the well.

5 The foregoing method can also be used to identify individual tracers at various locations on a solid support, including microplate wells, when the tracers can be separated into individual components by chromatographic techniques. The method is as described in the previous paragraph and the nature of the tracer is determined from the position on the support.

10 In still another aspect, the invention is directed to use of luminescence polarization to determine interactions or concentrations of nonpeptide components such as oligonucleotides and other organic compounds that show sequence-specific binding, as well as methods to assay viral maturation using these assays.

15 It also has been possible to conduct homogeneous luminescence polarization assays in microplates. PCT Patent Application Serial Nos. PCT/US98/14575 and PCT/US98/23095, which are incorporated herein by reference, describe a high throughput screening apparatus with a high color temperature continuous light source for such luminescence polarization and
20 other optical assay measurements. The contents of these applications are incorporated herein by reference. The assays further may be enhanced by using microplates with elevated wells that permit assay of smaller volumes, although the reduced volume of liquid makes more important the gradient of evaporation across the plate in its effect on concentration. These plates are described in
25 PCT Patent Application Serial No. PCT/US98/07505, which is incorporated herein by reference. An improvement provided by the invention permits correction for the altered concentrations that may result from this gradient.

Further aspects of the invention are illustrated without limitation in the following examples:

Example 1 – Peptide Libraries

In one aspect, the invention is directed to methods for preparing luminescently labeled peptide tracers systematically by taking advantage of combinatorial techniques. The labeled peptide can be synthesized by parallel methodologies, such as those described by Veber, D.F. *et al.*, *Current Opinions in Chemistry and Biology* (1997) 1:151-156. A multiplicity of putative tracer peptides designed for specific targets can thus be prepared in parallel by introducing the luminophore at defined positions within the peptide, for example, by synthesizing the peptides stepwise on solid phase supports and interrupting the synthesis by the insertion of a luminophore at various locations along the peptide chain. The compounds are of the formula



where FL represents a luminophore, AA represents an amino acid or an analog thereof that can be accommodated into a general peptide structure, and m and n are integers such that the sum of m and n is greater than 2 but less than 200:

$$2 < (m+n) < 200$$

The luminophore generally may be any composition capable of luminescence emission, excluding intrinsically fluorescent naturally occurring amino acids, such as tryptophan and tyrosine (or any of the other amino acids listed in Appendix 2). However, the luminophore may include extrinsic luminophores or amino acids labeled with an extrinsic luminophore (such as fluorescein or rhodamine). The extinction coefficient, quantum yield, Stokes' shift, luminescence lifetime, and other properties of the luminophore generally may be selected according to the intended use of the labeled peptide. The parallel synthesis can be conducted on a matrix, such as in the wells of a microplate, and the putative tracer peptides retained in the designated location in the microplate well. Individual tracers, whose structures are known by reference to

their location in the matrix, can then be tested with respect to the intended target, preferably using the improved methods of luminescence polarization assay described here. In addition to microplates, any addressable array is useable, such as microfabricated chips.

5 The result of the combinatorial synthesis is a library of peptides, which are candidates as tracers, that differ by the position of the luminophore in the peptide chain, as well as, if desired, the amino acid sequence of the chain *per se*. The library generally may have any number of peptides, but preferably will have a number of peptides equal to the number of wells in a microplate, or
10 some small fraction (e.g., 1/2, 1/3, etc.) thereof (to account for controls, calibrators and controls, etc.). Thus, the library may have 96, 384, 1536, or more peptides, among others. Peptides that successfully bind target can be identified by enhancement of their luminescence polarization in the presence of the target. The nature of the successful tracer is established by its method of
15 synthesis, as is understood in combinatorial synthesis methods generally.

Advantage can be taken of the availability of both FL-L and FL-S luminophores to identify suitable tracers for known targets. In this method, candidate tracers are placed into separate wells of a microplate or other suitable multicompartiment or solid support arrangement. This can be done by *in situ* synthesis of the tracer in each array position, for example, as in the case of the combinatorial tracers whose synthesis is described above, or various fractions from a separated mixture can be placed into separate locations on a solid support or in separate wells. The separate fractions of the mixture, separated on standard chromatographic media such as DEAE cellulose, CM cellulose,
20 phosphate-cellulose, hydroxyapatite, activated charcoal, and the like, or on chromatographic supports such as those used for thin-layer and paper chromatography, when immobilized on a solid support will have the capacity to enhance the luminescence polarization of even a long lifetime luminophore. A target coupled to a long lifetime luminophore will thus exhibit enhanced
25

luminescence polarization if bound to the tracer immobilized on the solid support. Thus, in wells that contain tracers that can successfully bind target, there will be a diminution in the degree of luminescence polarization for the luminophore (FL-L) coupled target. Thus, wells that show such a diminution in 5 polarization contain successful candidates.

This approach provides a straightforward method to assess a large number of tracers in relation to a defined target including those already identified by their preparation protocols, or tracers that have been fractionated into individual components. Successful tracers can then be coupled to a 10 luminophore, preferably FL-S, either before or after decoupling from the solid support. An FL-S luminophore is preferred, as the level of polarization will then be affected most certainly by binding of the tracer to the target.

In this application, the luminescently labeled peptides that bind to target are identified by mixing a multiplicity of labeled peptides with the target, and 15 discarding those that fail to bind. The peptides bound to target are then analyzed and synthesized afresh. In addition, PCT Patent Application Serial No. PCT/EP97/04077, which is incorporated herein by reference, describes a method of cell sorting using assays with luminescent peptides.

Example 2 – Cell-Signaling Assays

20 In another aspect, the invention is directed to nonpeptide luminescently labeled tracers comprising a luminescent label coupled to a nonpeptide ligand or a nonpeptide product of an activated receptor. Such tracers can be used in the method of the invention to assess the effect of putative agonists or antagonists on receptors or to assess the ability of a drug candidate to affect 25 receptor activation.

In one embodiment, a labeled ligand binds specifically to an activated form of a receptor, such as a cell-signaling receptor. The labeled ligand will exhibit a shift in luminescence polarization when bound to the activated receptor. The assay also can be constructed so as to assess the concentration of

activated receptor in a sample. This can be done in the context of membrane or tissue samples or in a cellular suspension. An increase in the polarization of luminescence emitted will be correlated with the concentration of activated receptor in the sample.

5 Assays of this type can also be used to determine the ability of candidate drugs to affect the level of activation of the receptor. The luminescence polarization assay is run in the presence and the absence of the candidate. Drugs that interfere with the activation of the receptor will diminish the level of enhanced polarization displayed.

10 An example of such a labeled ligand is a stabilized, nonhydrolyzable analog of GTP, for example, GTP(γ -S) or other stabilized GTP form. GTP binds to the activated forms of a class of receptors variously known as G protein-coupled receptors, serpentine receptors, seven-span membrane receptors, and 7 transmembrane-spanning domain receptors. Upon activation, 15 specific guanine nucleotide forms bind these receptors. GTP(γ -S) or other nonhydrolyzable form is then labeled with a luminophore such as fluorescein, such that the label still permits the activated-receptor-binding properties to be retained. Activation of the relevant receptor, such as the thrombin receptor or the various opioid receptors can then be measured in an appropriately designed 20 assay, if desired in the presence and absence of a candidate drug.

Another example of such a labeled ligand is a product of the activation of a receptor, such as cyclic AMP (cAMP) or cyclic GMP (cGMP). Labeled forms of these secondary messengers are useful in assays to determine signaling levels by establishing competing binding for an antibody or other 25 specific binding pair member between the labeled tracer and the cAMP or cGMP generated from the receptor activation.

The cell-signaling assays described here may be used in conjunction with compositions and techniques described in PCT Patent Application Serial No. ___, filed June 9, 2000, entitled *CELL-SIGNALING ASSAYS*, and naming J.

Richard Sportsman and Lawrence M. Kauvar as inventors, which is incorporated herein by reference.

Example 3 – Phosphorylation Assays

In yet another aspect, the invention is directed to specific labeled peptides containing phosphotyrosine that are useful in measuring activation of receptors characterized by phosphorylated tyrosines and to assess tyrosine phosphorylation generally. These specifically designed peptides show enhanced affinity for binding to the 4G10 antibody, which is directed to phosphorylated tyrosine. Phosphorylated tyrosine is an indicator of an activated form of the insulin receptor and many other receptors, such as EGF-receptor, and IGF-1 receptor, as well as nonreceptor tyrosine kinases, such as src, fyn, and many others known in the art. These peptides are of the formula

FL-A-pY-TGLSTRNQET-pY-ATH-NH₂;

15 FL-pY-pY-pY-IE-NH₂; and

FL-G-pY-NELNLGRREE-pY-DVL-NH₂.

Here, Y is the one-letter abbreviation for tyrosine, pY is phosphorylated tyrosine, and A, T, G . . . are one-letter abbreviations for other amino acids, as specified in Appendix 2.

Preferred embodiments for FL include various FL-S moieties, especially the 5-carboxy and 6-carboxy derivatives of fluorescein, which readily form amides at the N-terminus of the peptide.

These peptides are suitable tracers for competition assays with respect to analytes that contain phosphorylated tyrosine, such as the activated insulin receptor and natural or artificial substrates of it. They are advantageous over peptide labels known in the prior art by virtue of their enhanced affinity for specific binding partners for phosphorylated peptides containing phosphotyrosines. The assay methods may be extended to phosphoserine/theronine as well.

The peptides are thus useful as tracers in any luminescence polarization assay for phosphorylated peptides where the phosphorylation is associated with tyrosine residues. The peptides are added to a sample that contains or is suspected to contain such phosphorylated peptides along with an opposite 5 member of a specific binding pair involving these peptides. The peptides compete with any phosphorylated protein in the sample for the opposite member so that the degree of luminescence polarization observed in light emitted from the sample is inversely correlated with the concentration of phosphorylated protein in the sample. This determination also can be made as a 10 function of time if the activity of an enzyme that phosphorylates proteins is to be measured. In addition, the effect of compounds on such phosphorylation reactions can be studied by conducting the assay in the presence and in the absence of candidate compounds.

The phosphorylation assays described here may be used in conjunction 15 with compositions and techniques described in PCT Patent Application Serial No. _____, filed June 9, 2000, entitled *PHOSPHORYLATION ASSAYS*, and naming Wei Huang, Merl F. Hoekstra, Sandra K. Lee, Nicholas Cairns, Lawrence M. Kauvar, and J. Richard Sportsman as inventors, which is incorporated herein by reference.

20 **Example 4 – Nucleic Acid / Polymer Applications**

In yet another aspect, the methods of the invention can be applied to specific binding interactions involving binding partners that are nonpeptide based, including nucleic acids and polymers containing carbohydrates. Gibson *et al. Clin Chem* (1997) 43:1336-41. A number of applications are envisioned.

25 For example, luminescently labeled tracer oligonucleotides can be used to quantify mRNA production as a measure of expression. In particular, incorporation into an mRNA molecule will enhance the luminescence polarization of the labeled oligonucleotide probe.

Similarly, genetic mutations, including deletions, insertions, or rearrangements and duplications can be assessed by shearing genomic DNA and using luminescently labeled oligonucleotides as probes. In particular, repeat sequences are of interest as the frequency of binding under controlled 5 conditions can be compared as between nonaltered standards and genome fragments that may have additional hybridization sites or fewer hybridization sites than the standard. Very small changes, such as single nucleotide polymorphisms (SNPs), can be detected using this technique by careful control of the hybridization conditions.

10 Another approach to assessing mutations employs polymerase extension, which, by enlarging the molecule, enhances luminescence polarization. Polymerase extension will be interrupted by a mismatch in the tracer molecules.

15 In addition, binding to the class of compounds generally known as peptide-nucleic acids, which have a peptide backbone and purine or pyrimidine bases as side-chains, as described in U.S. Patent No. 5,864,010, can be assessed. Thus, these are members of specific binding pairs useful in assays involving oligonucleotide probes labeled with luminophores. These peptide-nucleic acids themselves can be used as the labeled probes as well.

20 In general, the luminescence polarization methods of the invention are applicable to any class of organic compounds where sequence-specific binding is exhibited, such as calcihaemicin 1, which has sequence-specific specificity for DNA cleavage (Drak, J. *et al.*, *Proc Natl Acad Sci USA* (1991) 88:7464-7468). The level of cleavage can, of course, be assessed by this technique 25 because the size, and thus the tumble time, of the molecule is altered by such cleavage.

Another class of oligonucleotides whose affinity can be determined by the techniques of the invention comprises aptamers whose affinity for targets can be determined by on/off rates of binding to targets. U.S. Patent No.

5,492,840 describes a flow cell surface plasmon resonance device for selecting high-affinity aptamers.

Still another application involving use of oligonucleotides is in the context of an assay for binding zinc finger proteins. Current assays for binding 5 of zinc finger proteins to defined DNAs require gel shift analyses, which are cumbersome and only semiquantitative. The methods of the invention can be applied to such assays by coupling double-stranded DNA of about 25 base pairs with a suitable luminophore to obtain a tracer for targets containing zinc finger motifs. Increases in polarization will be observed when the DNA binding 10 protein is present at concentrations above the K_d and the tracer is present at concentrations below the K_d . Binding may be observed within 60 minutes of incubation.

The nucleic acid / polymer assays described here may be used in conjunction with compositions and techniques described in U.S. Patent 15 Application Serial No. 09/494,407, which is incorporated herein by reference.

Example 5 – Viral Maturation

In yet another aspect, the invention is directed to application of luminescence polarization in a new context, namely, the assessment of viral maturation. Luminophores exhibiting long emission times are particularly 20 useful in this application.

For example, an antibody that recognizes an epitope that exists only in an assembled virion but not in the isolated component proteins can be provided with an FL-L moiety to detect the titer of assembled virion as a function of time. Alternatively, an antibody that recognizes epitopes characteristic of 25 intermediate stages of virion assembly that are no longer exposed in the completed virion can be used to monitor maturation. By adding the FL-L labeled antibody to the medium containing the assembling virions, the assembly can be followed as a change in polarization as a function of time.

Of course, by monitoring the progress of viral maturation, the effect of drugs on this process can be evaluated by conducting the experiment in the presence and absence of candidate drugs. Such drugs are believed to modulate the rate of virion assembly by interacting with the appropriate proteins 5 involved in this process. King, J. *et al. Q Rev Biol* (1980) 55:369-393.

Detecting drugs that bind to immature virus particles automatically enriches for drugs that interfere with viral maturation. PCT Patent Application Serial Nos. PCT/US98/06963 and PCT/US98/07171, which are incorporated herein by reference, describe creation of multidentate ligands with more than 10 tether points attached to a core structure of more than 10 kD; tethering, to one of these points, a luminophore with a long emission time would permit detection of binding the multidentate ligand to targets such as virions.

Example 6 – Affinity Constants

In yet another aspect, the invention may be used for determination of 15 affinity constants for interacting molecules. In Figure 2, an equilibrium analysis at various concentrations of labeled theophylline tracer and monoclonal antibody 8 permits calculation of the dissociation constant for these components. In Figure 3, determination of the on/off rates of interaction of labeled theophylline with a different monoclonal antibody is illustrated. In 20 using on/off rates, the dissociation constant is derived from a ratio of these rates. The on rate is measured by providing the components separately and measuring the rate of binding. The off rate is measured by providing the bound complex and measuring dissociation.

Example 7 – Volume Determinations

25 In yet another aspect, confocal optics may be used to judge the spatial extent of a sample, such as displacement, area, and volume. Confocal optics allows detection of light substantially exclusively from a sensed volume of a sample, as described in U.S. Patent No. 6,071,748, which is incorporated herein by reference. This sensed volume can be used to reduce signal-to-background

ratios by positioning the sensed volume away from the walls of a sample container, as described below in Example 8. This sensed volume also can be used to determine the spatial extent of a sample by positioning the sensed volume at various points along one or more axes intersecting the sample, and

5 determining the extent based on the number and position of points from which light is collected. (The sensed volume will detect light if positioned within the sample, and will not detect light (or will detect distinguishably different light) if positioned outside the sample.) Sample extent may be determined along directions parallel and/or perpendicular to an optical axis, and may be used to

10 determine areas and volumes by computing products of extent along two or three such directions, respectively.

This procedure also can be used to measure changes in volume. One advantage of this ability is reflected in a procedure to adjust the volume through dilution or evaporation, thus permitting alteration of concentrations in

15 the wells. The confocal optics monitors these changes in concentration that are based on volume adjustments as opposed to addition or subtraction of analyte. The ability to adjust concentrations in this way permits titration methods using the luminescence polarization technique to define affinity constants using equilibrium characteristics. In addition, on/off rates can be used to determine

20 dissociation constants. These measurements are independent of volume changes and merely measure binding as a function of time.

Example 8 – Improved-signal Assays

In yet another aspect, the invention may involve techniques for enhancing signals, signal-to-noise ratios, and/or signal-to-background ratios.

25 Signal may be enhanced in several ways, including (1) using a high color temperature light source, such as a xenon arc lamp, in a continuous illumination mode, (2) using a dichroic or multi-dichroic beamsplitter, and/or (3) using a sample holder whose shape is “matched” to the shape of the optical beam of the instrument, especially if the sample holder is elevated to bring the

sample closer to a detector. The high color temperature light source increases the number of usable photons, which is important because the lower limit of the signal-to-noise ratio is set by the square root of the total number of photons collected in the measurement. These enhancements are described in more detail 5 in the following U.S. Patent Applications, which are incorporated herein by reference: Serial No. 09/349,733, Serial No. 09/478,819, and Serial No. 09/494,407.

Signal-to-noise ratios can be enhanced at least in part by increasing signals, for example, by using the techniques described in the previous 10 paragraph.

Signal-to-background ratios can be enhanced in several ways, including (1) using confocal optical systems having a sensed volume to avoid luminescence from the microplate walls, (2) selecting a microplate or other substrate that increases the signal and reduces the luminescent background 15 from materials in the microplate, (3) selecting the light sources, luminescence filters, optics, signal collection electronics, and mechanical system used in the luminescence detection optical system for maximum signal-to-background ratio, and (4) utilizing signal processing, background subtraction, and luminescence lifetime techniques, particularly FLAMe™ methodology for 20 background reduction, as described below. These enhancements are described in more detail in the following U.S. Patent and U.S. Patent Applications, which are incorporated herein by reference: Patent No. 6,071,748, Serial No. 09/349,733, Serial No. 09/478,819, and Serial No. 09/494,407.

Thus, the invention provides a variety of improvements and additional 25 applications for luminescence polarization assays.

Appendix 1— Luminescence Polarization Assays —

Luminescence polarization assays involve the absorption and emission of polarized light. (Polarization describes the direction of light's electric field, which generally is perpendicular to the direction of light's propagation.) In a luminescence polarization assay, specific molecules within a composition are labeled with one or more luminescent moieties (i.e., "luminophores"). The composition then is illuminated with polarized excitation light, which preferentially excites luminophores having absorption dipoles aligned parallel to the polarization of the excitation light. These molecules subsequently decay by preferentially emitting light polarized parallel to their emission dipoles. The extent of polarization of the total emitted light depends on the extent of molecular reorientation during the time interval between luminescence excitation and emission, which is termed the luminescence lifetime, τ . In turn, the extent of molecular reorientation depends on the luminescence lifetime and the size, shape, and environment of the reorienting molecule. Thus, luminescence polarization assays may be used to quantify binding reactions and enzymatic activity, among other applications. In particular, molecules commonly rotate (or "tumble") via diffusion with a rotational correlation time τ_{rot} that is proportional to their volume, or the cube of their radius of gyration. (This cubic dependence on radius makes polarization assays very sensitive to binding.) Thus, during their luminescence lifetime, relatively large molecules will not reorient significantly, so that their total luminescence will be relatively polarized. In contrast, during the same time interval, relatively small molecules will reorient significantly, so that their total luminescence will be relatively unpolarized.

The relationship between polarization and intensity is expressed by the following equation:

$$P = \frac{I_{\parallel} - I_{\perp}}{I_{\parallel} + I_{\perp}} \quad (\text{A1})$$

Here, P is the polarization, I_{\parallel} is the intensity of luminescence polarized parallel to the polarization of the excitation light, and I_{\perp} is the intensity of luminescence polarized perpendicular to the polarization of the excitation light. P generally varies from zero to one-half for randomly oriented molecules (and zero and one for aligned molecules). If there is little rotation between excitation and emission, I_{\parallel} will be relatively large, I_{\perp} will be relatively small, and P will be close to one-half. (P may be less than one-half even if there is no rotation; for example, P will be less than one-half if the absorption and emission dipoles are not parallel.) In contrast, if there is significant rotation between absorption and emission, I_{\parallel} will be comparable to I_{\perp} , and P will be close to zero. Polarization often is reported in milli- P units ($1000 \times P$), which for randomly oriented molecules will range between 0 and 500, because P will range between zero and one-half.

Polarization also may be described using other equivalent quantities, such as anisotropy. The relationship between anisotropy and intensity is expressed by the following equation:

$$r = \frac{I_{\parallel} - I_{\perp}}{I_{\parallel} + 2I_{\perp}} \quad (\text{A2})$$

Here, r is the anisotropy. Polarization and anisotropy include the same information, although anisotropy may be more simply expressed for systems containing more than one luminophore. In the description and claims that follow, these terms may be used interchangeably, and a generic reference to one should be understood to imply a generic reference to the other.

The relationship between polarization and rotation is expressed by the Perrin equation:

$$\left(\frac{1}{P} - \frac{1}{3} \right) = \left(\frac{1}{P_0} - \frac{1}{3} \right) \cdot \left(1 + \frac{\tau}{\tau_{\text{rot}}} \right) \quad (\text{A3})$$

Here, P_0 is the polarization in the absence of molecular motion (intrinsic polarization), τ is the luminescence lifetime (inverse decay rate) as described above, and τ_{rot} is the rotational correlation time (inverse rotational rate) as described above.

The Perrin equation shows that luminescence polarization assays are most sensitive when the luminescence lifetime and the rotational correlation time are similar. Rotational correlation time is proportional to molecular weight, increasing by about 1 nanosecond for each 2,400 dalton increase in molecular weight (for a spherical molecule). For shorter lifetime luminophores, such as fluorescein, which has a luminescence lifetime of roughly 4 nanoseconds, luminescence polarization assays are most sensitive for molecular weights less than about 40,000 daltons. For longer lifetime probes, such as Ru(bpy)₂dcbpy (ruthenium 2,2'-bipyridyl 4,4'-dicarboxyl-2,2'-bipyridine), which has a lifetime of roughly 400 nanoseconds, luminescence polarization assays are most sensitive for molecular weights between about 70,000 daltons and 4,000,000 daltons.

Appendix 2

The following table lists the one- and three-letter abbreviations for the twenty naturally occurring amino acids commonly found in biological systems.

<i>Amino acid</i>	<i>Three-letter Abbreviation</i>	<i>One-letter abbreviation</i>
Alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic acid	Asp	D
Asparagine or aspartic acid	Asx	B
Cysteine	Cys	C
Glutamine	Gln	Q
Glutamic acid	Glu	E
Glutamine or glutamic acid	Glx	Z
Glycine	Gly	G
Histidine	His	H
Isoleucine	Ile	I
Leucine	Leu	L
Lysine	Lys	K
Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	Thr	T
Tryptophan	Trp	W
Tyrosine	Tyr	Y
Valine	Val	V

Although the invention has been disclosed in its preferred forms, the specific embodiments thereof as disclosed and illustrated herein are not to be considered in a limiting sense, because numerous variations are possible. As used herein, singular terms do not preclude the use of more than one of the 5 associated element, and embodiments using more than one of a particular element are within the spirit and scope of the invention. Applicants regard the subject matter of their invention to include all novel and nonobvious combinations and subcombinations of the various elements, features, functions, and/or properties disclosed herein. No single feature, function, element or 10 property of the disclosed embodiments is essential. The following claims define certain combinations and subcombinations of features, functions, elements, and/or properties that are regarded as novel and nonobvious. Other combinations and subcombinations may be claimed through amendment of the present claims or presentation of new claims in this or a related application. 15 Such claims, whether they are broader, narrower, equal, or different in scope to the original claims, also are regarded as included within the subject matter of applicants' invention.

WE CLAIM:

1. A combinatorial method to prepare a library of peptide tracers for use in a luminescence-based assay having the formula

5 $\text{AA}_m\text{-FL-AA}_n$,

wherein each AA is independently an amino acid, FL is a luminophore different than a naturally occurring amino acid, and m and n are integers such that the sum of m and n is greater than 2 but less than 200, which method comprises

10 synthesizing said peptide tracers stepwise on solid phase supports through the addition of an AA or FL, wherein FL is inserted at the same or different position, thereby varying or not the values of m and n and the type of AA selected so as to obtain a library of labeled peptides tracers.

15 2. A library of labeled peptides synthesized by the method of claim 1.

3. The library of claim 2, wherein the number of labeled peptides in the library is at least 96.

20 4. The library of claim 3, wherein the number of labeled peptides in the library is at least 384.

5. A library of luminescent peptide tracers comprising a multiplicity of peptides of the formula



wherein each AA is independently an amino acid, FL is a luminophore 5 different than a naturally occurring amino acid, and m and n are integers such that the sum of m and n is greater than 2 but less than 200, and

wherein the values for m and n differ among the individual peptide members of the library.

10 6. The library of claim 5, wherein the number of labeled peptides in the library is at least 96.

7. The library of claim 6, wherein the number of labeled peptides in the library is at least 384.

15 8. A method to identify a tracer for use in a luminescence polarization assay for a target which tracer is the opposite member of a specific binding pair comprising said target which method comprises

20 placing candidate tracers at separate, defined locations on a solid support,

exposing said locations on the support to a target labeled with a long-lifetime emission luminophore (FL-L),

subjecting the solid support to polarized light comprising a wavelength for excitation of said FL-L so as to effect emission of polarized light,

25 measuring the degree of polarization of the emitted light at each defined location on said solid support, and

identifying as a tracer useful in luminescence polarization assays for said target, a tracer at a defined location having a low degree of measured polarization.

9. The method of claim 8 further comprising labeling the identified successful tracer with a short-lifetime luminophore before or after cleaving said tracer from the solid support.

5 10. The method of claim 8, wherein said locations on solid support are wells of a microplate.

11. The method of claim 8, wherein said displaying of candidate tracers is accomplished by synthesis of said tracers at the various locations on 10 said solid support.

12. A method to determine the level of expression of a gene which method comprises

15 contacting a sample comprising said gene with a luminophore coupled to an oligonucleotide which is the opposite member of a specific binding pair of which the mRNA transcribed from said gene is the other member of the pair, and

measuring the luminescence polarization light emitted from said luminophore as a measure of the expression of said gene.

20 13. A method to determine the level or rate of viral maturation which method comprises

25 contacting a sample containing said virus with a luminophore coupled to a member of a specific binding pair whose opposite member is characteristic of the maturation of said virus, and

measuring the luminescence polarization in said sample, optionally as a function of time, whereby an increase in luminescence polarization of the sample identifies the binding pair member as binding to a virion, said virion being the mature form of said virus.

14. A method to determine the dissociation constant of the members of a specific binding pair which method comprises

measuring the rate of dissociation of members of the specific binding pair by monitoring the change in luminescence polarization of a sample 5 containing the binding pair in coupled form,

measuring the rate of association of the members of said specific binding pair by monitoring the luminescence polarization of a sample containing the members of said pair in uncoupled form, and

calculating the dissociation constant as the ratio of said rates.

10

15. A method for determining the spatial extent of a sample positioned within a sample holder which method comprises

measuring the light transmitted from a sensed volume positioned at a plurality of points within or adjacent the sample holder, and

15

determining the spatial extent of the sample based on the presence or nature of the light transmitted from each point.

16. The method of claim 15, where the spatial extent is a volume.

20

17. The method of claim 15 further comprising

repeating the steps of measuring and determining at two different times, and


calculating the change in spatial extent between the two different times.

25

18. The method of claim 17, wherein the change in spatial extent represents a diminution in volume.

19. The method of claim 15, wherein the sample holder is a microplate.

20. The method of claim 19 further comprising the steps of
5 measuring and determining for at least two wells in the microplate.



FP Binding




Figure 2

FP Rate Constants





Figure 3

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/15774

A. CLASSIFICATION OF SUBJECT MATTER																									
IPC(7) : G01N 33/543, 53 US CL : Please See Extra Sheet.																									
According to International Patent Classification (IPC) or to both national classification and IPC																									
B. FIELDS SEARCHED																									
Minimum documentation searched (classification system followed by classification symbols)																									
U.S. : 435/7.1, Dig. 35, Dig. 41, Digl 46, Dig. 49; 530/334, 333; 436/518																									
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																									
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) cas, west																									
C. DOCUMENTS CONSIDERED TO BE RELEVANT																									
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																							
Y	US 5,874,214 A (NOVA et al) 23 February 1999, col.41, line 9 up to col. 45, line 41.	1-7																							
Y	US 5,824,772 A (VINCENT et al) 20 October 1998, col. 3, line 40 up to col. 6, line 7.	1-7																							
Y	US 5,760,188 A (BEAUDET et al) 02 June 1998, col. 6, line 55 up to col. 7, line 40	1-7																							
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																									
<table border="0" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; padding: 2px;">* Special categories of cited documents:</td> <td style="width: 10%; padding: 2px;">*T*</td> <td style="width: 60%; padding: 2px;">later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td style="padding: 2px;">*A*</td> <td style="padding: 2px;">document defining the general state of the art which is not considered to be of particular relevance</td> <td style="padding: 2px;">*X*</td> <td style="padding: 2px;">document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td style="padding: 2px;">*E*</td> <td style="padding: 2px;">earlier document published on or after the international filing date</td> <td style="padding: 2px;">*Y*</td> <td style="padding: 2px;">document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td style="padding: 2px;">*L*</td> <td style="padding: 2px;">document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td style="padding: 2px;">*&*</td> <td style="padding: 2px;">document member of the same patent family</td> </tr> <tr> <td style="padding: 2px;">*O*</td> <td style="padding: 2px;">document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td style="padding: 2px;">*P*</td> <td style="padding: 2px;">document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A*	document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E*	earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L*	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&*	document member of the same patent family	*O*	document referring to an oral disclosure, use, exhibition or other means			*P*	document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																							
A	document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																						
E	earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																						
L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&*	document member of the same patent family																						
O	document referring to an oral disclosure, use, exhibition or other means																								
P	document published prior to the international filing date but later than the priority date claimed																								
Date of the actual completion of the international search	Date of mailing of the international search report																								
15 SEPTEMBER 2000	12 OCT 2000																								
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer  T. WESSENDORF Telephone No. (703) 308-0196																								

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/15774

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort, justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-7

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/15774

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

435/7.1, Dig. 35, Dig. 41, Digl 46, Dig. 49; 530/334, 333; 436/518

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I. claim(s) 1-7, drawn to method of making a library of peptide traces and library made.

Group II, claim(s) 8-11, drawn to method to identify a peptide tracer.

Group III, claim(s) 12, drawn to the method of determining the level of expression of a gene.

Group IV, claim(s) 13, drawn to a method of determining the level of viral maturation.

Group V, claim(s) 14, drawn to a method of determining a dissociation constant.

Group VI, claim(s) 15-20, drawn to a method of determining a dissociation constant

The inventions listed as Groups I-VI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: each of the inventions are drawn to different methods where the method steps lack the same or corresponding special technical features producing distinct results.